1. Home
  2. NRXP vs BOLD Comparison

NRXP vs BOLD Comparison

Compare NRXP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • BOLD
  • Stock Information
  • Founded
  • NRXP 2015
  • BOLD 2018
  • Country
  • NRXP United States
  • BOLD United States
  • Employees
  • NRXP N/A
  • BOLD N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • BOLD
  • Sector
  • NRXP Health Care
  • BOLD
  • Exchange
  • NRXP Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • NRXP 32.6M
  • BOLD 30.3M
  • IPO Year
  • NRXP N/A
  • BOLD 2024
  • Fundamental
  • Price
  • NRXP $3.50
  • BOLD $1.07
  • Analyst Decision
  • NRXP Strong Buy
  • BOLD Buy
  • Analyst Count
  • NRXP 4
  • BOLD 3
  • Target Price
  • NRXP $28.50
  • BOLD $4.00
  • AVG Volume (30 Days)
  • NRXP 295.0K
  • BOLD 260.9K
  • Earning Date
  • NRXP 08-13-2025
  • BOLD 08-11-2025
  • Dividend Yield
  • NRXP N/A
  • BOLD N/A
  • EPS Growth
  • NRXP N/A
  • BOLD N/A
  • EPS
  • NRXP N/A
  • BOLD N/A
  • Revenue
  • NRXP N/A
  • BOLD N/A
  • Revenue This Year
  • NRXP N/A
  • BOLD N/A
  • Revenue Next Year
  • NRXP N/A
  • BOLD N/A
  • P/E Ratio
  • NRXP N/A
  • BOLD N/A
  • Revenue Growth
  • NRXP N/A
  • BOLD N/A
  • 52 Week Low
  • NRXP $1.10
  • BOLD $1.00
  • 52 Week High
  • NRXP $6.01
  • BOLD $4.72
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 66.15
  • BOLD N/A
  • Support Level
  • NRXP $2.90
  • BOLD N/A
  • Resistance Level
  • NRXP $3.61
  • BOLD N/A
  • Average True Range (ATR)
  • NRXP 0.28
  • BOLD 0.00
  • MACD
  • NRXP -0.03
  • BOLD 0.00
  • Stochastic Oscillator
  • NRXP 64.59
  • BOLD 0.00

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: